Introduction: Dapagliflozin is a selective
with no comparator. Dapagliflozin was administered as monotherapy (n = 249) or combination therapy (n = 479) with existing antihyperglycemic agents (sulfonylurea, glinides, metformin, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase- 4 inhibitors, or glucagon-like peptide-1 receptor agonists) to Japanese patients with T2DM and inadequate glycemic control for 52 weeks. Treatment with dapagliflozin was initiated at 5 mg/day and titrated to 10 mg/day as required.
Trial Registration: ClinicalTrials.gov #NCT01294436.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic and progressive disorder associated with an increased risk of microvascular and macrovascular complications [1] . Despite the wide array of available medications, many patients do not achieve the recommended level of glycemic control [2] . Most antihyperglycemic drugs target a reduction in insulin resistance or enhance insulin secretion and, due to the progressive nature of the disease, often lose efficacy over time.
Inhibitors of sodium glucose co-transporter 2 (SGLT2) are a new class of oral antihyperglycemic drugs (OADS) whose efficacy is independent of insulin sensitivity and secretion. Healthy kidneys filter *180 g of glucose daily [3] , the majority of which is reabsorbed at the level of the proximal tubule through SGLT2 [4] . SGLT2 inhibitors improve glycemic control through a reduction in filtered glucose reabsorption and a resultant increase in urinary glucose excretion. As this class of drug is not dependent on the ability of the pancreatic b cells to secrete insulin, they have the potential to be used throughout the course of the disease.
Dapagliflozin is an orally active, highly selective SGLT2 inhibitor that has been shown to significantly improve glycemic control. Across a global clinical development program involving analyses of Phase IIB/III trials, treatment with dapagliflozin, as monotherapy or in conjunction with preexisting OADs, was associated with reductions in glycosylated hemoglobin (HbA 1c ) and fasting plasma glucose (FPG) as well as reductions or stabilization of body weight and systolic blood pressure (SBP) in patients with T2DM [5] [6] [7] [8] [9] [10] [11] [12] [13] .
In Japanese patients with T2DM, the efficacy of dapagliflozin on glycemic parameters and body weight has been demonstrated over 12-24 weeks [14, 15] . In the 24-week trial, a greater proportion of Japanese patients with T2DM receiving dapagliflozin 10 mg experienced adverse events (AEs) (64.8%) compared with the placebo group (51.7%); these were primarily AEs unrelated to treatment, such as nasopharyngitis and dental caries in patients receiving dapagliflozin 10 mg [14, 15] . In general, the safety and tolerability of dapagliflozin reported in Japanese patients were similar to those experienced by patients throughout the global dapagliflozin clinical development program.
The aim of this study was to evaluate the safety and tolerability of long-term treatment (up to 52 weeks) with dapagliflozin as monotherapy or in combination with other OADs, including sulfonylureas (SU), glinides, metformin, a-glucosidase inhibitors (AGI), thiazolidinediones (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists.
METHODS AND MATERIALS

Study Design
A single-treatment arm, open-label, Phase III study was carried out in 100 centers in Japan over 52 weeks (Clinicaltrials.gov identifier NCT01294436). The study comprised a 2-week screening period, a 4-week lead-in period, a 52-week treatment period with a single active treatment without any comparator, and a 3-week follow-up period. The study design is shown in Fig. 1 .
The active study treatment was given across eight subgroups, including one monotherapy and seven individual combination therapy groups (SU, glinides, metformin, AGI, TZD, DPP-4 inhibitors, and GLP-1 agonists). Patients in the monotherapy group receiving therapy at enrollment underwent a 6-week washout period before a 4-week lead-in period in an attempt to eliminate effects of any prior therapy. Conference on Harmonization/Good Clinical Practice (GCP), the applicable regulatory requirements, and the AstraZeneca policy on bioethics. All patients provided informed consent prior to entering the study. Fig. 1 Study design a monotherapy and b combination therapy. The asterisk indicates that the wash-out period was applicable only for subjects who received medical treatment for diabetes until enrollment. Double asterisks indicate that Week 1 was applicable exclusively for the subgroup of combination therapy with GLP-1 agonists
Key Inclusion Criteria
Men or women aged C20 years with a diagnosis of T2DM were eligible for inclusion in the study. Women of childbearing potential were required to be using a highly effective method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after study completion, and to have a negative urine pregnancy test within 72 h prior to the start of study treatment and at each visit thereafter.
Monotherapy
Patients who were given the study drug were considered for rescue treatment by the investigator. Down-titration to 5 mg of dapagliflozin was not allowed after up-titration to 10 mg/day of dapagliflozin; if the investigator determined down-titration to 5 mg/day of dapagliflozin was necessary, the patient was withdrawn from the study.
In the combination therapy subgroups, dose reduction of the basal OAD (except for SU) was not allowed during the treatment period for any condition. If dose reduction of the basal OAD (except for SU) was needed, the patient was withdrawn from the study. A reduction of the SU dose was required if two or more readings of plasma glucose B70 mg/dL (B3.9 mmol/L) were recorded at any visit after week 0.
Rescue Criteria
Following up-titration to 10 mg/day dapagliflozin for C8 weeks, if HbA 1c was still [8% in patients from week 24 to week 52, rescue treatment was administered at the investigators' discretion. In the monotherapy subgroup, only one additional OAD could be added and gradually increased up to the approved maximum dose. In the combination therapy group, doses of the basal OAD were gradually increased up to the approved maximum doses and then, if necessary, only one additional OAD was added and gradually increased up to the approved maximum dose at the discretion of investigators following local regulation and treatment guidelines in Japan [18] .
Outcome Measures
The primary endpoints were safety and tolerability, including AEs, laboratory parameters, electrocardiogram, vital signs, hypoglycemic events, eGFR (calculated using the Japanese guideline recommended equation [16, 17] 
RESULTS
Patient disposition is shown in Fig. 2 Table 1) .
Safety
The frequency of AEs observed over the 52-week treatment period with dapagliflozin was 79.1%
for the monotherapy group and 72.4% for the combination groups (Table 2 ) (the range across the combination groups was 63.9-78.9%). AEs were mostly mild or moderate in intensity, and the frequency of serious AEs was 5.6% in the monotherapy group and 3.1% for the AE adverse event, eGFR estimated glomerular filtration rate, SE standard error a Based on a predefined list of events fractures, and volume-related events were low and similar in the monotherapy and combination therapy groups (Table 2) . eGFR values declined from week 0 to week 8 in both monotherapy and combination therapy groups (change from baseline, -2.9 and The effects of dapagliflozin on clinical laboratory data are shown in Table 3 . Reductions in urine sodium were observed in both the monotherapy and the combination 
Efficacy
Reductions in HbA 1c levels from baseline to week 52 with dapagliflozin were the same in the monotherapy and combination therapy groups (-0.7% for both) ( Table 4 ; Fig. 3a) . No patients were rescued due to lack of glycemic control in either group. In addition, reductions in HbA 1c were similar across each of the individual combination therapies (range -0.5 to -0.9%) (Fig. 4) . In both the monotherapy and combination therapy groups, reductions in HbA 1c from baseline to week 52 with dapagliflozin were greater in patients with higher baseline HbA 1c (Fig. 5a) . Similarly, in both groups, the reductions in HbA 1c with dapagliflozin were more pronounced in patients with higher baseline kidney function (eGFR) (Fig. 5b) . A greater proportion of patients achieved HbA 1c levels\7% with dapagliflozin in the monotherapy group (53.4%) versus the combination therapy group (35.1%) ( Table 4) .
Following treatment with dapagliflozin, total body weight was reduced to a similar degree in the monotherapy and combination therapy groups (Table 4 ; Fig. 3b ). In the monotherapy treatment group, 33.7% of patients achieved a body weight loss of C5% compared with 24.1% in the combination therapy group (Table 4) .
Body mass index, waist circumference, FPG levels, fasting insulin, and fasting C-peptide were also reduced to a similar extent in the dapagliflozin monotherapy and combination therapy groups (Table 4) . SBP and DBP were reduced in both the monotherapy group and the combination therapy groups. Approximately half of all patients in either group with baseline SBP C130 mmHg achieved reductions in SBP to \130 mmHg.
Numerical increases were observed in total, LDL, and HDL cholesterol and free fatty acid levels in both the monotherapy and combination therapy groups (Table 4 ). Triglyceride levels dropped in both therapy groups.
Effect of Up-Titration of Dapagliflozin on Glycemic Control
The first patients were up-titrated from dapagliflozin 5 mg/day to 10 mg/day at week agonists. Urinary glucose excretion associated with the treatment of dapagliflozin in Japanese patients was comparable to that observed in a Western population [19, 20] . Urinary tract and genital infections, often associated with SGLT2
inhibitor treatment as a consequence of the associated glucosuria [21, 22] , were comparatively low (\4%) in this study compared with pooled data from a global development program that included 12 placebo-controlled Phase IIB and III studies (4.3% and 4.8%, respectively) [23, 24] . The effects of dapagliflozin on secondary endpoints in this study were similar to those seen in other studies. Dapagliflozin was effective in improving glycemic control as both a monotherapy and in combination with other OADs. Consistent with previous studies, the improvement in glycemic control in this study was dependent on the baseline level of hyperglycemia [25] ; a greater effect of dapagliflozin was observed in patients with higher baseline HbA 1c . In addition, the improvement in glycemic control was reduced in patients with compromised renal function reflecting results observed in the Western population [26] . It should be noted that the majority of patients in this study had mild renal impairment. Patients treated with dapagliflozin maintained a mean weight loss of 2-3 kg over 52 weeks, and this reduction was similar between monotherapy and combination therapy groups. This likely reflects a loss of calories associated with the mechanism of action of dapagliflozin. In general, although there is some concern for sarcopenia with SGLT2 inhibitors in slim Japanese patients, the weight loss observed with dapagliflozin is considered to be primarily a result of a loss of fat mass [7] . A reduction in blood pressure was also observed and is presumably associated with osmotic diuresis and body weight reduction. In addition, dapagliflozin had no long-term effects on calcium, which was also observed in longerterm studies of up to 2 years [7, 26] . Overall, the results reported here over 52 weeks are consistent with those reported previously in Japanese patients and with those from the overall dapagliflozin clinical program. The safety and efficacy of dapagliflozin were comparable in the monotherapy and It should be taken into account when assessing the study population that this was not a randomized study, and patients with ongoing antidiabetic treatment in the combination therapy groups clearly have a different history of T2DM than those in the monotherapy group.
CONCLUSION
In conclusion, regardless of background antihyperglycemic medication, dapagliflozin was well tolerated and effective in improving glycemic control and reducing body weight in Japanese patients with inadequately controlled T2DM.
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